Telithromycin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Telithromycin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Diarrhea | 10.8% |
| Nausea | 7.9% |
| Headache | 5.8% |
| Dizziness (excl. vertigo) | 3.7% |
| Dysgeusia | 3.6% |
| Vomiting | 2.9% |
| Loose stools | 2.3% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSPMDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.